

PRESS RELEASE

01 August 2025 15:00:00 CEST



Lipum AB (publ) has decided to postpone the interim report Q2 2025 to August 28, 2025

The previously announced publication date for the interim report Q2 2025 was August 14. The publication has now been postponed to August 28, 2025.

Contacts

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se

About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments

[Lipum AB \(publ\) has decided to postpone the interim report Q2 2025 to August 28, 2025](#)